{
    "2018-08-22": [
        [
            {
                "time": "2018-08-22",
                "original_text": "Health Care Sector Update for 08/22/2018: EXAS,PFE,ARGX,PHG,SNGX",
                "features": {
                    "keywords": [
                        "Health",
                        "Care",
                        "Sector",
                        "Update",
                        "EXAS",
                        "PFE",
                        "ARGX",
                        "PHG",
                        "SNGX"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "Health Care Sector Update for 08/22/2018: ARGX,PHG,SNGX",
                "features": {
                    "keywords": [
                        "Health",
                        "Care",
                        "Sector",
                        "Update",
                        "ARGX",
                        "PHG",
                        "SNGX"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "AbbVie Is Focused on Diversifying Its Portfolio in 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Diversifying",
                        "Portfolio",
                        "2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "Oncology Is a Major Growth Driver for AbbVie in 2018",
                "features": {
                    "keywords": [
                        "Oncology",
                        "Growth",
                        "Driver",
                        "AbbVie",
                        "2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "European shares steady as trade talks, U.S. politics fuel uncertainty",
                "features": {
                    "keywords": [
                        "European",
                        "shares",
                        "steady",
                        "trade",
                        "talks",
                        "U.S.",
                        "politics",
                        "uncertainty"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "AbbVie Has Raised Its EPS Guidance for 2018",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Raised",
                        "EPS",
                        "Guidance",
                        "2018"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "Argenx Shares Up After AbbVie Exercises Option To License Immuno-Oncology Drug",
                "features": {
                    "keywords": [
                        "Argenx",
                        "Shares",
                        "Up",
                        "AbbVie",
                        "Option",
                        "License",
                        "Immuno-Oncology",
                        "Drug"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive",
                        "Topline",
                        "Results",
                        "Phase",
                        "3",
                        "Extension",
                        "Study",
                        "Elagolix",
                        "Uterine",
                        "Fibroids"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "AbbVie Announces Positive Results From Phase 3 Extension Study On Elagolix",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive",
                        "Results",
                        "Phase",
                        "3",
                        "Extension",
                        "Study",
                        "Elagolix"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-08-22",
                "original_text": "AbbVie doubles down on cancer project with biotech group Argenx",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "doubles",
                        "down",
                        "cancer",
                        "project",
                        "biotech",
                        "group",
                        "Argenx"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}